Vor Biopharma is developing shielded transplants that utilize Hematopoietic Stem Cell (HSC) biology and genome engineering to protect healthy cells while targeting cancer cells in patients with acute myeloid leukemia (AML) and other blood cancers. This approach aims to delay relapse and provide potentially curative treatment options post-transplant.
Funding
Funding not disclosed
Founders
Product
Problem
Patients with acute myeloid leukemia (AML) and other blood cancers face a high risk of relapse after hematopoietic stem cell transplantation (HSCT). Current post-transplant treatments often lack the specificity to target cancer cells without harming healthy cells, limiting their effectiveness and causing significant toxicity.
Solution
Vor Biopharma is developing shielded hematopoietic stem cell (eHSC) transplants designed to protect healthy cells from post-transplant therapies while allowing for targeted elimination of cancer cells. The company's approach involves genome engineering of HSCs to make them resistant to specific drugs or immunotherapies. This shielding allows clinicians to administer these therapies post-transplant to eradicate residual cancer cells without damaging the newly transplanted, healthy blood cells. By shielding healthy cells, Vor Bio aims to delay or prevent relapse, enabling potentially curative treatment options for patients with AML and other blood cancers.
Target Audience
The primary target audience includes patients with acute myeloid leukemia (AML) and other blood cancers who are undergoing or have undergone hematopoietic stem cell transplantation, as well as medical professionals specializing in hematology and oncology.
Features
- Genome engineering of hematopoietic stem cells (HSCs) to create engineered HSCs (eHSCs) resistant to specific therapies.
- Shielded transplants that protect healthy blood cells from the toxic effects of post-transplant treatments.
- Enables the use of targeted therapies, such as antibody-drug conjugates (ADCs) and CAR-T cells, post-transplant to eliminate residual cancer cells.
- Proprietary platform combining HSC biology, genome engineering, and CAR-T cell technology.
- Manufacturing process for efficient production of investigational eHSC products.